Thomas Meier Appointed as New CEO of Medios AG, Signaling Strategic Growth Phase
Medios AG appoints Thomas Meier as new CEO to drive expansion in the European Specialty Pharma market, bringing international leadership experience from Swiss CDMO Bachem Holding AG.
The Supervisory Board of Medios AG has appointed Thomas Meier as the new Chief Executive Officer effective February 1, 2026, marking a significant leadership transition for the German specialty pharmaceutical company. Meier succeeds Matthias Gaertner, who will remain in office until December 31, 2025, concluding a ten-year tenure that saw substantial growth and development of the company.
Thomas Meier brings extensive international experience to Medios AG, having served as CEO of Swiss Contract Development and Manufacturing Organization Bachem Holding AG since 2020. His background includes previous roles as Chief Operations Officer at Bachem and Head of Manufacturing at Peninsula Laboratories in San Carlos, California, from 2001 to 2004. This appointment signals Medios's intention to accelerate growth and strengthen its position in the competitive European pharmaceutical landscape.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this leadership change. "With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth," Samson stated. "We are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers."
The leadership transition comes at a critical time for Medios as the company positions itself for expansion in the European Specialty Pharma market. Medios operates as Germany's first listed specialty pharmaceutical company, with shares trading on the Frankfurt Stock Exchange's Prime Standard and inclusion in the SDAX selection index. The company maintains operations across Germany, the Netherlands, Belgium and Spain, focusing on innovative solutions for individualized medicine.
Thomas Meier expressed enthusiasm for his new role, stating, "I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios's position in the European Specialty Pharma market."
The appointment underscores Medios's commitment to advancing individualized medicine, an area the company has pioneered to make innovative therapies accessible through partnerships with pharmacies, specialist practices and pharmaceutical companies. More information about the company's approach to personalized healthcare can be found at https://app.medios.group/en/individualizedmedicine.
Medios has scheduled several important financial communications in the coming weeks, including the Quarterly Statement as of September 30, 2025 on November 11, participation in the mwb inspired Conference in Hamburg on November 12, and the Berenberg European Conference at Fairmont Windsor Park in Great Britain on December 4. These events will provide further insight into the company's strategic direction under new leadership.